Generic Name and Formulations:
Irinotecan HCl 20mg/mL; soln for IV infusion after dilution.
Indications for CAMPTOSAR:
Metastatic colorectal cancer, as 1st line therapy with 5-FU and leucovorin, or as monotherapy if disease recurs or progresses after fluorouracil-based therapy.
Give by IV infusion over 90 mins. Combination therapy: 125mg/m2 on days 1, 8, 15, 22; or, 180mg/m2 on days 1, 15, 29; both: give every 6 weeks. Monotherapy: 125mg/m2 on days 1, 8, 15, 22, then 2-week rest; or, 350mg/m2 once every 3 weeks. Elderly (≥70yrs), pelvic or abdominal radiotherapy, performance status of 2, increased bilirubin, homozygous UGT1A1*28 allele, or toxicity: reduce initial dose. May pretreat with antiemetics and/or atropine. Dose modifications: see full labeling.
Not for use as part of 5-FU/LV "Mayo Clinic" regimen except in certain circumstances (see full labeling). If late diarrhea occurs, promptly treat with loperamide; suspend until bowel function normalizes. Monitor blood counts; suspend if neutropenic fever or ANC <1000/mm3 occurs. Volume depleted. Renal or hepatic impairment. Dialysis: not recommended. Gilbert's syndrome or abnormal glucuronidation. Discontinue if interstitial pulmonary disease occurs. Avoid extravasation. Elderly. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.
Concomitant irradiation: not recommended. Concomitant CYP3A4 inducers (eg, phenytoin, phenobarbital, carbamazepine, rifampin, St. John's wort), CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole), UGT1A1 inhibitors (eg, atazanavir, gemfibrozil): not recommended. Discontinue strong CYP3A4 inhibitors at least 1 week before initiating irinotecan. Avoid diuretics or laxatives if diarrhea occurs. May affect neuromuscular blocking agents.
Nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, mucositis, neutropenia, leukopenia, anemia, thrombocytopenia, asthenia, pain, fever, infection, abnormal bilirubin, alopecia, weight decrease; hypersensitivity reactions (discontinue if occurs), pulmonary toxicity.
Testing considerations: UGT1A1 mutation analysis
Single-dose vial (2mL, 5mL, 15mL)—1
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Improving the Care of Aging Adults Living With HIV
- Infection Prevention Differs Between Small, Large Hospitals
- International Antiviral Society-USA Updates Recommendations for HIV Treatment and Prevention
- Previous Missed Appointments Predict Likelihood of Trend in Patients With HIV
- FDA Warns Against Long-Term Azithromycin Use for Some
- Identifying the Source of C difficile in Hospitalized Patients
- Antibiotics Often Unnecessary for Sacral Pressure Ulcers Complicated by Osteomyelitis
- Sensitivity and Specificity of 7 Treponemal Tests for Syphilis Diagnosis
- Automated EHR Algorithm More Effective Than Nurse-Driven Protocol for HCV, HIV Screening
- A Pan-Tuberculosis Regimen: The Debate Continues
- HCV Eradication in HIV/HCV-Coinfection Decreases Immune Activation
- Tolerability of Switching to Long-acting Cabotegravir Plus Rilpivirine From Current HIV-1 Regimen
- Time to Blood Culture Positivity Predictive of Mortality in S Aureus Infective Endocarditis
- C difficile Tied to Increased Graft Loss in Solid Organ Recipients
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd